AVCO Avalon GloboCare Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVCO

Price (delayed)

$0.96

Market cap

$81.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.14

Enterprise value

$85.3M

Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics ...

Highlights
Avalon GloboCare's gross margin has surged by 57% YoY and by 13% QoQ
Avalon GloboCare's gross profit has increased by 46% YoY and by 11% from the previous quarter
Avalon GloboCare's quick ratio has shrunk by 61% QoQ and by 58% YoY
The equity has declined by 32% year-on-year and by 31% since the previous quarter
Sector: Healthcare
Industry: Medical Care Facilities
Website: http://www.avalon-globocare.com
Peers: OPI OLP OHI

Key stats

What are the main financial stats of AVCO
Market
Shares outstanding
85.41M
Market cap
$81.99M
Enterprise value
$85.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
25.1
Price to sales (P/S)
60.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
63.21
Earnings
Revenue
$1.35M
EBIT
-$10.91M
EBITDA
-$10.48M
Free cash flow
-$6.34M
Per share
EPS
-$0.14
Free cash flow per share
-$0.07
Book value per share
$0.04
Revenue per share
$0.02
TBVPS
$0.12
Balance sheet
Total assets
$10.38M
Total liabilities
$7.15M
Debt
$4M
Equity
$3.23M
Working capital
-$2.35M
Liquidity
Debt to equity
1.24
Current ratio
0.36
Quick ratio
0.22
Net debt/EBITDA
-0.32
Margins
EBITDA margin
-776.7%
Gross margin
34.6%
Net margin
-821.3%
Operating margin
-802.9%
Efficiency
Return on assets
-102.7%
Return on equity
-255.8%
Return on invested capital
-104.2%
Return on capital employed
-162.9%
Return on sales
-808.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVCO stock price

How has the Avalon GloboCare stock price performed over time
Intraday
1.04%
1 week
6.67%
1 month
0.62%
1 year
-16.52%
YTD
-14.29%
QTD
-2.29%

Financial performance

How have Avalon GloboCare's revenue and profit performed over time
Revenue
$1.35M
Gross profit
$467,210
Operating income
-$10.83M
Net income
-$11.08M
Gross margin
34.6%
Net margin
-821.3%
Avalon GloboCare's gross margin has surged by 57% YoY and by 13% QoQ
Avalon GloboCare's gross profit has increased by 46% YoY and by 11% from the previous quarter
AVCO's operating income is up by 35% year-on-year and by 6% since the previous quarter
AVCO's operating margin is up by 30% year-on-year and by 4.6% since the previous quarter

Growth

What is Avalon GloboCare's growth rate over time

Valuation

What is Avalon GloboCare stock price valuation
P/E
N/A
P/B
25.1
P/S
60.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
63.21
The EPS has grown by 30% year-on-year and by 7% since the previous quarter
The equity has declined by 32% year-on-year and by 31% since the previous quarter
The stock's price to book (P/B) is 17% more than its last 4 quarters average of 21.5
The stock's price to sales (P/S) is 9% less than its last 4 quarters average of 65.8
The revenue has contracted by 8% YoY

Efficiency

How efficient is Avalon GloboCare business performance
AVCO's ROIC is up by 38% YoY and by 5% QoQ
AVCO's return on assets is up by 31% year-on-year and by 5% since the previous quarter
The return on sales has grown by 24% year-on-year and by 4.5% since the previous quarter
AVCO's return on equity is up by 17% year-on-year but it is down by 2.4% since the previous quarter

Dividends

What is AVCO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVCO.

Financial health

How did Avalon GloboCare financials performed over time
The company's total assets is 45% higher than its total liabilities
Avalon GloboCare's quick ratio has shrunk by 61% QoQ and by 58% YoY
The current ratio has declined by 49% year-on-year and by 46% since the previous quarter
The company's debt is 24% higher than its equity
The debt to equity has soared by 70% YoY and by 46% QoQ
The equity has declined by 32% year-on-year and by 31% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.